<DOC>
	<DOCNO>NCT02959437</DOCNO>
	<brief_summary>This open-label , Phase 1/2 study subject advance metastatic solid tumor . The study divide 2 part ( Part 1 2 ) . Part 1 dose-escalation assessment evaluate safety tolerability DNA methyltransferase inhibitor azacitidine combination program death receptor-1 ( PD-1 ) inhibitor pembrolizumab indoleamine 2,3-dioxygenase ( IDO-1 ) inhibitor epacadostat . Once recommended dos determine , subject previously treat NSCLC microsatellite-stable colorectal cancer ( CRC ) enrol expansion cohort Part 2 .</brief_summary>
	<brief_title>Azacitidine Combined With Pembrolizumab Epacadostat Subjects With Advanced Solid Tumors ( ECHO-206 )</brief_title>
	<detailed_description />
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Willingness provide write informed consent study . Part 1 : Subjects histologically cytologically confirm advanced metastatic solid tumor fail prior standard therapy ( disease progression ; subject refusal intolerance also allowable ) . Part 2 : Subjects histologically cytologically confirm NSCLC : Stage IIIB metastatic ( Stage IV ) NSCLC ( accord American Joint Committee Cancer 7th edition guideline ) disease progression available therapy advance metastatic disease know confer clinical benefit , intolerant treatment , refuse standard treatment . Prior systemic regimen must include previously approve therapy , include platinumcontaining chemotherapy regimen ; tyrosine kinase inhibitor tumor driver mutation ; checkpoint inhibitor approve ( except Cohort A1 , must checkpoint inhibitornaive ) . Must disease progression prior PD1pathway target agent ( Cohort A2 ) must PD1 pathwaytargeted treatment naive ( Cohort A1 ) . Subjects recurrent ( unresectable ) metastatic CRC : Have histologically confirm microsatellite stable ( MSS ) CRC . Stage IV MSS CRC ( accord American Joint Committee Cancer 7th edition guideline ) disease progression available therapy advance metastatic disease know confer clinical benefit , intolerant treatment , refuse standard treatment . Prior systemic regimen must include previously approve therapy , include fluoropyrimidine , oxaliplatin , irinotecanbased chemotherapy ; antiVEGF therapy ( contraindication ) ; KRAS wild type contraindication , antiepidermal growth factor receptor ( EGFR ) therapy ; progress last administration approve therapy . Has baseline tumor biopsy specimen available willingness undergo pretreatment ontreatment tumor biopsy obtain specimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Laboratory parameter within protocoldefined range . Receipt anticancer medication investigational drug within define interval first administration study drug . Has recover toxic effect prior therapy â‰¤ Grade 1 . Active inactive autoimmune disease syndrome . Active infection require systemic therapy . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . History presence abnormal ECG , investigator 's opinion , clinically meaningful . Has receive live vaccine within 30 day plan start study therapy . Prior receipt IDO inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>NSCLC</keyword>
	<keyword>CRC</keyword>
</DOC>